ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits ...

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA ...

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...

Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.